Synchronous gastrointestinal cancer and gastrointestinal stromal tumors: a single-institution experience by Jian Du et al.
RESEARCH Open Access
Synchronous gastrointestinal cancer and
gastrointestinal stromal tumors: a single-
institution experience
Jian Du, Ning Shen*, Hai-Shan He, Xiao-Lan Fu, Jing-Zhong Wang and Chong-Zhou Mao
Abstract
Background: A study was conducted to investigate the clinicopathological features and survival outcomes of
gastrointestinal stromal tumors (GISTs) that are synchronous with other gastrointestinal cancers.
Methods: Clinical and pathological data of 286 patients with primary GIST from a single institution from January
2009 to December 2014 were reviewed.
Results: The entire study population comprised 286 patients with GISTs. Of these patients, 167 (58.4 %) were males
and 119 (41.6 %) were females. The median age was 58 years old (in the range 29–86 years). A total of 47 patients
were diagnosed with GISTs synchronous with other digestive tract malignancies (synchronous group), whereas 239
patients were diagnosed with non-synchronous disease (non-synchronous group). The concomitant digestive tumors
in 27, 12, 7, and 1 patients were diagnosed as gastric carcinoma, esophageal carcinoma, colorectal carcinoma, and
pancreatic adenocarcinoma, respectively. Compared with the synchronous group, the non-synchronous group
exhibited a higher percentage of increased mitotic count (P = 0.011). The difference in tumor diameter between the
two groups was statistically significant (P < 0.001). Patients in the non-synchronous group exhibited larger tumor size
than the patients in the synchronous group (5.9 ± 3.5 cm vs. 1.6 ± 0.4 cm, P < 0.001). The majority of GIST lesions in the
synchronous group were located in the stomach (P = 0.020). Lower risk stratifications and worse ECOG performance
statuses were observed in the synchronous group (P < 0.001) than in the non-synchronous group. The 5-year overall
survival rate was significantly higher in patients with no synchronous digestive tract malignancies than in patients with
synchronous disease (70.8 vs. 34.1 %, P < 0.001).
Conclusions: Patients with GIST synchronous with other gastrointestinal cancers show worse prognosis than those
with non-synchronous tumors. Clinicians should pay more attention to this subgroup.
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Background
Gastrointestinal stromal tumors (GISTs) are the most
common type of mesenchymal tumors in the gastro-
intestinal tract [1]. The incidence of GISTs in China
has increased in recent years [2]. Most GISTs are diag-
nosed incidentally during investigative or therapeutic
procedures for unrelated diseases. The ratio of patients
with GIST that is diagnosed to be synchronous with an-
other digestive neoplasm is reportedly in the range of
17.1 to 37.9 % [3–5]. Numerous patients with GISTs
that are synchronous with other neoplasms have been
described previously, but most of these cases were pub-
lished in case reports or are included in studies with
small sample sizes.
Although major advances in the management and mo-
lecular biology of GISTs have been achieved in the past
two decades, little is still known about GISTs coexisting
with gastrointestinal tumors. Furthermore, the effect of
the coexistence of GISTs and other primary gastrointes-
tinal neoplasm on patients remains controversial [6, 7].
Familiarity with occurrence patterns of GISTs synchron-
ous with other neoplasms is important for both patholo-
gists and surgeons. In the present study, we analyzed the
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clinicopathological characteristics and treatments of a
large sample size of patients with GISTs synchronous




Patients with gastrointestinal tumor synchronous with
other digestive malignancies were identified by clinical
data at the Department of General Surgery, Suining
Municipal Hospital of Traditional Chinese Medicine
from January 2009 to December 2014. All primary
GISTs were resected and histologically diagnosed by a
pathologist. Patients with GISTs diagnosed as recurrent
or metastatic and those with malignancies other than
malignant digestive tumors with GISTs were excluded.
The Institutional Review Board and Ethics Committee of
the Suining Municipal Hospital of Traditional Chinese
Medicine deemed that an ethical review was unnecessary
for this retrospective study.
Data collection and follow-up
Data on age at diagnosis, gender, size, and tumor location,
Eastern Cooperative Oncology Group (ECOG) perform-
ance status, medication, surgical outcome, mitotic count,
and survival outcome of the patients were collected. The
risk stratification of GISTs was evaluated according to the
modified National Institutes of Health classification [8].
Surgery performed for the management of the tumors was
classified into three categories, as follows: R0 (complete
gross and microscopic resection), R1 (with microscopic
residual lesions), and R2 resections (with retention of any
gross residual tumors). Follow-up was conducted by tele-
phone call, office visit, or outpatient clinic visit from
February 2015 to May 2015. Abdominal CT, blood routine
examination, and evaluation of liver and kidney functions
were performed.
Statistical analysis
Overall survival (OS) was defined as the duration from
the start of treatment until death from any cause or the
last follow-up visit. All statistical analyses were per-
formed using the Statistical Package for Social Sciences
(SPSS Inc., Chicago, IL, USA). The differences between
groups were analyzed using ANOVA for continuous var-
iables and χ2 test or Fisher’s exact test for categorical
data. Measurement data were expressed as mean ±
standard deviation. Survival analysis was performed
using the Kaplan-Meier method and the results were
compared using a log-rank test. Differences with two-
sided P < 0.05 were considered statistically significant.
Results
Patients’ characteristics
The entire study population comprised 286 patients with
GISTs, including 167 (58.4 %) males and 119 (41.6 %)
females. The median age was 58 years old (29–86 years
old). Table 1 summarizes the baseline characteristics of
Table 1 The demographic and tumor characteristics of patients
with GISTs





≤ 60 165 57.7





≤ 1 190 66.4
≥ 2 96 33.6
Tumor size (cm)
≤ 5 127 44.4
> 5 159 55.6
Tumor location
Stomach 219 76.6
Small intestine 52 18.2
Othersa 15 5.2
Mitotic count (50 HPF)
≤ 5 173 60.5
6–10 86 30.1
> 10 27 9.4
NIH risk categories










Preoperative IM therapy 15 5.2
Adjuvant IM therapy 141 49.3
Metastasis at diagnosis or surgery 31 10.8
Median follow-up (range, months) 32 (5–76) -
Hospital stay (days, mean ± SD) 17.3 ± 4.5 -
GISTs gastrointestinal stromal tumors, NIH National Institutes of Health, HPF
high power fields, IM imatinib mesylate, SD standard deviation
aIncluding omentum, retroperitoneal, mesentery of large and small intestine,
and pelvic mass
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the GIST patients. Of the 286 patients enrolled, 47 pa-
tients were diagnosed with GISTs that are synchronous
with other digestive tract malignancies (synchronous
group), whereas 239 patients exhibited no synchronicity
(non-synchronous group). The number of cases with tu-
mors located in the stomach, small intestine, and other
parts (omentum, retroperitoneum, mesentery of the
large and small intestine, and pelvis) were 219 (76.6 %),
52 (18.2 %), and 15 (5.2 %), respectively. In the syn-
chronous group, the tumors in 2 out of 47 patients were
preoperatively discovered by electronic endoscopy and
subsequently diagnosed as GISTs; Fig. 1a, b). The data
are shown in Table 1. Among the patients, 15 and 141
received preoperative imatinib mesylate (IM) and
adjuvant IM therapy, respectively. A total of 31 patients
had tumor metastasis at the time of diagnosis or during
surgery. R0 resection was completed in 274 patients
(95.8 %).
Tumor characteristics
A total of 47 patients were diagnosed with GISTs that
are synchronous with other digestive tract malignancies.
The concomitant digestive tumors in 27 (57.4 %), 12
(25.5 %), 7 (14.9 %), and 1 (2.1 %) patients were diag-
nosed as gastric carcinoma, esophageal carcinoma, colo-
rectal carcinoma, and pancreatic adenocarcinoma,
respectively. For the patients with gastric carcinoma,
TNM staging were as follows: I in 4, II in 7, III in 15,
and IV in 1. For the patients with esophageal carcinoma,
1 case was diagnosed as stage I, 5 as stage II, and 6 as
stage III. Compared with the synchronous group, the
non-synchronous group showed a higher percentage
with increased mitotic counts (P = 0.011). The difference
in tumor diameter between the two groups was statisti-
cally significant (P < 0.001). Patients in the non-
synchronous group exhibited larger tumor sizes than
those in the synchronous group (5.9 ± 3.5 cm vs. 1.6
± 0.4 cm, P < 0.001). The majority of the GIST lesions
in the synchronous group were located in the stom-
ach (P = 0.028). Lower risk stratifications and worse
ECOG performance statuses were observed in the
synchronous group than in the non-synchronous
group (P < 0.001). Meanwhile, no statistically signifi-
cant difference in age, gender, and hospital stay was
noted between the two groups (Table 2). Overall, 53
GISTs were found in the synchronous group due to
multiple GISTs which were detected in 5 patients.
Survival outcomes
With a median follow-up duration of 32 months (5–76
months), 53 patients died on the last follow-up. In the
non-synchronous group, 76 patients presented with GIST-
specific progression. The 5-year OS rate was
significantly higher in patients with no synchronous
digestive tract malignancies than in those with syn-
chronous disease (70.8 vs. 34.1 %, P = 0.000; Fig. 2).
The median survival rate was not achieved by pa-
tients in the non-synchronous group in contrast to
23 months for patients with GISTs synchronous with
digestive tract malignancies.
Discussion
GISTs reportedly occur synchronously with other gastro-
intestinal neoplasms, including gastric adenocarcinoma
and lymphoma, esophageal cancer, colon adenocarcin-
oma, pancreatic cancer, and hepatocellular carcinoma
[9–13]. The most common GIST-associated malignancy
is gastrointestinal cancer, which is mainly located in the
stomach and then in the esophagus [5, 14]. In our study,
47 out of 286 patients were diagnosed with primary
GISTs that are synchronous with primary gastrointes-
tinal neoplasm and the concomitant digestive tumors
were in 27 (57.4 %) and 12 (25.5 %) patients which were
diagnosed as gastric carcinoma and esophageal carcin-
oma; this findings were similar to their results. So far,
the actual incidence of the coexistence of GISTs and
other tumors remains to be determined. Subclinical
Fig. 1 a, b Electronic endoscopy image showing tumors located in the stomach (a) and the large intestine (b)
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microscopic gastric GISTs have been reported in the
past 3 years. Agaimy et al. found that microscopic gas-
tric GISTs presented in 22.5 % of patients aged 50 years
old or older through a series of consecutive autopsies
[6]. Kawanowa et al. also reported that microscopic
GISTs coexisted with 35 % of resected specimens of gas-
tric carcinomas [4]. With more experience and expertise
in the endoscopic examination of the upper gastrointes-
tinal tract, the recognition of incidental subepithelial
lesions has significantly increased accordingly. One
retrospective study reported the prevalence of subepithe-
lial gastric masses (0.36 %) during routine endoscopy
[15]. Results of these studies suggested that GISTs are
far more common than previously estimated. Similarly,
the synchronous occurrence of GISTs and other primary
gastrointestinal tumors may have been underestimated.
According to literature, sporadic GISTs usually arise in
the stomach in 40 to 70 % of cases, the small intestine in
20 to 40 % of cases, and the esophagus, colorectum, and
other regions of the abdominal cavity, such as the retro-
peritoneal tissue and mesentery, in less than 10 % of the
cases [6, 16]. In the present study, the synchronous
GISTs were also most frequently found in the stomach
(43 cases, 91.5 %), followed by the small intestine
(6.4 %), and rectum (1 case, 2.1 %). Apparently, the most
common site of GISTs between synchronous group and
non-synchronous group was similar in this study.
In our study, most (95.7 %, n = 45) of the synchronous
GISTs were accidentally discovered during the surgical
exploration of the other gastrointestinal cancer. Only
4.3 % of the coexistent GISTs were identified during pre-
operative examination. Therefore, a careful search for
synchronous GISTs should be carried out during gastro-
intestinal cancer surgeries. Large, population-based stud-
ies have demonstrated that 15–30 % of GISTs are
asymptomatic and are usually identified incidentally dur-
ing surgeries or by postmortem examination [17]. In a
study by Miettinen et al., 1765 gastric GISTs were inves-
tigated. Results showed that the GISTs were detected in-
cidentally during abdominal surgery or a medical
procedure for gallbladder disease in 2.4 % and colorectal
carcinomas or adenoma in 1.6 % of the cases [18].
Tumor sizes of GISTs vary in different studies. In the
present study, the synchronous GISTs showed a mean
size of 1.6 ± 0.4 cm, which was slightly larger than the
results from previous investigations. In a study by
Agaimy et al., the “microscopic” gastric GISTs in autopsy
specimens measured 2–10 mm in size (mean: 5 mm) [6].
Another study reported a median size of 1.5 mm (0.2–
4.0 mm) of microscopic GISTs coexisting with gastric
adenocarcinoma [4]. Management of GISTs with sizes less
than 2 cm is controversial, as the natural history of such
neoplasms is unknown. Several retrospective studies dem-
onstrated that the resection of small GISTs presents a fa-
vorable oncological outcome. Otani and colleagues
resected 35 gastric GISTs (2–5 cm in size) [19]. During
the follow-up period (median, 53 months), no local or dis-
tant recurrences were found in cases with neoplasms
Table 2 Demographic and clinicopathologic data between two
groups
Variables Synchronous
group (n = 47, %)
Non-synchronous
group (n = 239, %)
P value
Age, years 66.4 ± 5.6 61.2 ± 4.2 0.231
Gender 0.614
Male 29 (61.7) 138 (57.7)
Female 18 (38.3) 101 (42.3)
ECOG score <0.001
≤ 1 16 (34.0) 174 (72.8)
≥ 2 31 (66.0) 65 (27.2)
Tumor site 0.028
Stomach 43 (91.5) 176 (73.6)
Small intestine 3 (6.4) 48 (20.1)
Othersa 1 (2.1) 15 (6.3)
Tumor size, cm 1.6 ± 0.4 5.9 ± 3.5 <0.001
Median
(range, cm)




≥ 10 0 (0.0) 27 (11.3)






42 (89.4) 76 (31.8)
Intermediate
and high




Yes 2 (4.3) 139 (58.2)

















18.6 ± 5.3 16.9 ± 4.2 0.209
ECOG Eastern Cooperative Oncology Group, HPF high power field, NIH National
Institutes of Health, IM imatinib mesylate
aIncluding omentum, retroperitoneal, mesentery of large and small intestine,
and pelvic mass
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under 4 cm. Moreover, in a retrospective study of 207 pa-
tients who underwent gastrectomy or esophagectomy for
non-GIST neoplasms, 15 synchronous GISTs in the upper
gastrointestinal tract of 11 (5.3 %) patients were found
with an average size of 0.5 cm (0.1–4.0 cm) [7]. After a
median follow-up of 11 months (2–36 months), no patient
experienced GIST recurrence. Synchronous GISTs that
were incidentally found during the resection of other
gastrointestinal neoplasms may not negatively affect long-
term survival, although they often pose very low or low
risk of malignant potential. Small GISTs (<2 cm) may be
asymptomatic and nonmalignant when diagnosed but
have a potential for malignant transformation. In the
present study, there were five patients with intermediate/
high risk in the non-synchronous group, and they might
more likely to experience tumor progression than that of
patients with very low/low risk.
Currently, surgical resection is the common treatment
for GIST patients. However, a certain risk remains in
cases where only the primary gastrointestinal tumors are
resected completely. The residual GISTs may grow and
ulcerate, cause obstruction and bleeding, and pose diffi-
culties to the postoperative evaluation of the primary
gastrointestinal neoplasms. Therefore, R0 resection
should be achieved in all surgical procedures for GISTs.
Small GISTs can be safely performed by means of endo-
scopic resection, as reported by Shen et al. [20]. As
GISTs rarely (about 5 %) metastasize to lymph nodes,
routine lymph node dissection around GIST is often un-
necessary. The present data showed that the OS rate
was significantly higher in patients without digestive
tract malignancies. This finding is consistent with those
of a previous report [5].
Multiple studies showed that among patients with pri-
mary GISTs, 14–27 % have synchronous gastrointestinal
neoplasms. By contrast, only 3–5 % of the general popu-
lation may have the gastrointestinal tumors, which re-
veals a conspicuous discrepancy between the two
groups. Currently, various hypotheses attempt to explain
the synchronous existence of GISTs with other gastro-
intestinal tumors. These hypotheses include the relations
to genetic predisposition, environmental risk factors,
mutagenic effect from previous radiation or chemother-
apy, Helicobacter pylori infection, chronic atrophic gas-
tritis, and coincidental findings [21–24]. Whether the
synchronicity is a simple incidental association or a legit-
imate causal relationship between the occurrences of the
two tumors is still unknown. Tada et al. [23] believed
that a stomach harboring a leiomyosarcoma may have a
tendency to develop malignant epithelial lesions. On the
basis of accumulated reports, Maiorana et al. [24] pro-
posed that in cases of synchronicity, a single carcino-
genic agent may have interacted with two neighboring
tissues and induced the development of tumors of differ-
ent origins in the same organ, such as the gene mutation
of KIT or PDGFRA. However, Ponti et al. [25] specu-
lated that a small subset of GISTs that are negative for
the KIT- and PDGFRA-activating mutations may be
inherited and may occur as part of a multi-neoplastic
disease. Some researchers believe in the existence of a
Fig. 2 Kaplan-Meier estimates of overall survival (OS) rate. OS was significantly higher in the non-synchronous group than in the synchronous
group (P < 0.001)
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certain carcinogen that can act on different tissue cells
in the same or adjacent organs and can result in two
types of tissue differentiation. Other hypotheses, such as
that related to H. pylori infection, still lack identifiable
experimental evidence. However, some researchers re-
ported that there was no relationship existing between
the synchronous occurrence of these two tumors and
this phenomenon is only coincidental [26].
Conclusions
In conclusion, the synchronous occurrence of GISTs and
other gastrointestinal tumors is more common than pre-
viously estimated. Surgeons should be vigilant in recog-
nizing a coexisting tumor before or during surgery and
be prepared to modify the surgical plan accordingly. Pa-
tients with GISTs synchronous with other gastrointes-
tinal cancers showed worse prognoses than those with
non-synchronous disease. Further studies are required to
elucidate the exact molecular and genetic mechanisms
underlying the carcinogenesis and progression associat-
ing GISTs with synchronous tumors.
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